Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
99334 trials found · Page 5 of 4967
-
CRISPR gene therapy frees patients from lifelong blood transfusions
Disease control CompletedThis is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPC…
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated May 30, 2026 12:51 UTC
-
Engineered immune cells take aim at tough childhood leukemia
Disease control OngoingSJCAR19 is a research study seeking to evaluate the use of chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of pediatric, adolescent and young adult patients with relapsed or refractory CD19+ acute lymphoblastic leukemia (ALL). CAR the…
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 30, 2026 12:51 UTC
-
Gene therapy breakthrough cuts bleeding in severe hemophilia b
Disease control CompletedThis is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile. The study drug is identified as AAV5-hFIXco-Padua (AMT- 061). AMT-061 is a recombinant adeno-associated viral vector of seroty…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 29, 2026 14:20 UTC
-
Gene therapy offers new hope for babies with rare 'Bubble Boy' disease
Disease control Recruiting nowThis study aims to determine if a new method can be used to treat Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a severe form of primary immunodeficiency caused by mutations in the DCLRE1C gene. This method involves transferring a normal copy of the DCLRE1C gene …
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 29, 2026 14:19 UTC
-
New Low-Toxicity transplant could cure sickle cell in kids
⭐️ CURE ⭐️ Recruiting nowThis multisite prospective study seeks to determine if HLA-identical sibling donor transplantation using alemtuzumab, low dose total-body irradiation, and sirolimus (Sickle transplant Using a Nonmyeloablative approach, "SUN") can decrease the toxicity of transplant while achievin…
Phase: PHASE2 • Sponsor: Robert Nickel • Aim: ⭐️ CURE ⭐️
Last updated May 26, 2026 12:12 UTC
-
Gene therapy breakthrough: one dose may help babies with rare muscle disease
Disease control CompletedTo evaluate the safety and efficacy of intravenous onasemnogene abeparvovec-xioi in pre-symptomatic patients with SMA and 2 or 3 copies SMN2
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
Gene therapy offers hope for 'bubble boy' disease without lifelong drugs
Disease control Recruiting nowThis is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years…
Phase: PHASE1, PHASE2 • Sponsor: David Williams • Aim: Disease control
Last updated May 27, 2026 23:07 UTC
-
Gene therapy aims to cure sickle cell disease in pioneering trial
⭐️ CURE ⭐️ OngoingA promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease. In gene therapy, the investigators introduce new genetic…
Phase: PHASE1 • Sponsor: David Williams • Aim: ⭐️ CURE ⭐️
Last updated May 26, 2026 08:20 UTC
-
Gene therapy offers hope for kids with fatal brain disorder
Disease control CompletedOTL-200 is autologous CD34+ cells transduced with lentiviral vector containing human arylsulfatase A (ARSA) complementary deoxyribonucleic acid (cDNA) used for the treatment of MLD. MLD is an autosomal recessive lysosomal storage disorder (LSD) characterized by severe and progres…
Phase: PHASE2 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated May 30, 2026 12:49 UTC
-
Breakthrough CAR t-cell therapy outshines standard care for hard-to-treat lymphoma
Disease control CompletedThe goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated May 27, 2026 12:03 UTC
-
HIV prevention breakthrough? monthly shot could replace daily pill for women
Prevention OngoingThis study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated May 29, 2026 14:19 UTC
-
New hope for kids with leukemia: smarter chemo dosing aims for higher cure rates
⭐️ CURE ⭐️ OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Phase: PHASE3 • Sponsor: Dana-Farber Cancer Institute • Aim: ⭐️ CURE ⭐️
Last updated May 26, 2026 12:12 UTC
-
New hope for aggressive breast cancer: personalized therapy aims for cure
⭐️ CURE ⭐️ OngoingInvestigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy wi…
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: ⭐️ CURE ⭐️
Last updated May 14, 2026 12:02 UTC
-
HIV prevention breakthrough: a shot instead of a daily pill?
Prevention CompletedThis study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
Phase: PHASE2, PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated May 30, 2026 12:48 UTC
-
One pill could end sleeping sickness: new trial shows promise
⭐️ CURE ⭐️ CompletedThe goal of this study is to assess efficacy and safety of acoziborole in adult participants with Trypanosoma brucei gambiense (T.b. gambiense) HAT, either early- or intermediate-stage HAT (first arm) or late-stage HAT (second arm). Participants will receive 3 tablets of 320 mg a…
Phase: PHASE2, PHASE3 • Sponsor: Drugs for Neglected Diseases • Aim: ⭐️ CURE ⭐️
Last updated May 27, 2026 11:51 UTC
-
Major dengue vaccine trial shows promise in protecting kids
⭐️ VACCINE ⭐️ CompletedThe main purpose of this study is to evaluate the efficacy of 2 doses of Tetravalent Dengue Vaccine Candidate (TDV) in preventing symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 4 to 16 year old participants.
Phase: PHASE3 • Sponsor: Takeda • Aim: ⭐️ VACCINE ⭐️
Last updated May 29, 2026 14:19 UTC
-
High-Dose stem cell transplant aims to cure rare immune disease
⭐️ CURE ⭐️ OngoingChronic granulomatous disease (CGD) affects white blood cell function. Currently, the only curative treatment is bone marrow transplant to replace the abnormal stem cells with new ones (donor cells) capable of making a normal immune system. Transplant problems include graft versu…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ CURE ⭐️
Last updated May 26, 2026 12:12 UTC
-
Breakthrough trial aims to cure young cancer patients with less radiation
⭐️ CURE ⭐️ CompletedThe EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensifica…
Phase: PHASE3 • Sponsor: University of Giessen • Aim: ⭐️ CURE ⭐️
Last updated May 29, 2026 14:16 UTC
-
Early treatment may stall SMA: study shows promise in infants
Disease control CompletedThe primary objective of the study is to examine the efficacy of multiple doses of Nusinersen administered intrathecally in preventing or delaying the need for respiratory intervention or death in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (SMA)…
Phase: PHASE2 • Sponsor: Biogen • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
Stem cell transplant offers lifesaving hope for rare immune disorder
Disease control OngoingBackground: -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types of cancers, including blood cancers. A stem cell transplant is a life-saving treatment for this cond…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 27, 2026 11:50 UTC